PrecisionCHD™

About Cardio Diagnostics Holdings

Cardio Diagnostics Holdings is on a mission to combat cardiovascular disease through its innovative, AI-integrated epigenetic-genetic testing platform. The company has achieved key milestones with the commercial launch of its Epi+Gen CHD™ risk assessment test and the development of its PrecisionCHD™ diagnostic aid. Its strategy centers on securing broader insurance reimbursement, pursuing regulatory clearances to expand test utility, and establishing strategic partnerships to integrate its technology into large healthcare systems. As a micro-cap public company, it is in a critical commercial and validation stage, aiming to demonstrate clinical utility and drive adoption.

About CardioDiagnostics Inc.

Cardio Diagnostics is a commercial-stage biotech company with a mission to transform cardiovascular care from reactive to proactive using its unique AI-powered epigenetic platform. The company has achieved key milestones by launching its first commercial tests, Epi+Gen CHD and PrecisionCHD, targeting the massive and underserved market for early coronary heart disease detection. Its strategy involves a multi-pronged commercial approach, engaging healthcare providers, employers, and biopharma partners to drive adoption and generate data-driven insights across the care continuum.

Therapeutic Areas